<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196455</url>
  </required_header>
  <id_info>
    <org_study_id>MO18646</org_study_id>
    <nct_id>NCT01196455</nct_id>
  </id_info>
  <brief_title>Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Clinical Study of Capecitabine in Combination With Mitomycin C as First-Line Treatment in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croatian Cooperative Group for Clinical Research in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Croatian Cooperative Group for Clinical Research in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-comparative efficacy and safety study of Capecitabine and
      Mitomycin C as first-line treatment in patients with previously untreated metastatic breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>average 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to disease progression</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine and Mitomycin C</intervention_name>
    <description>Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks
Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks</description>
    <other_name>Capecitabine (Xeloda)</other_name>
    <other_name>Mitomycin C (Mutamycin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed breast cancer

          -  Metastatic breast cancer, having at least one target lesion according to the RECIST
             criteria. Bone metastases, leptomeningeal disease, ascites, pleural or pericardial
             effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not
             acceptable as target lesions. Target lesions must be ≥ 10 mm longest diameter measured
             in one dimension using spiral CT, or ≥ 20 mm longest diameter measured in one
             dimension using conventional techniques. In addition to the definitions pertaining to
             the target lesion(s) from the RECIST criteria above, the target lesion(s) must not
             have been previously irradiated (newly arising lesions in previously irradiated areas
             are acceptable).

          -  Age &gt; 18 years

          -  Signed informed consent obtained prior to initiation of any study-specific procedures
             or treatment

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast
             disease

          -  Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment

          -  Life expectancy &lt; 3 months

          -  Not-ambulatory or with an ECOG performance status &gt; 1

          -  Insufficient hematological, renal and hepatic functions:

          -  hemoglobin &lt; 8.0 g/dL

          -  absolute neutrophils count (ANC) &lt; 1.5 x 109/L

          -  platelet count &lt; 100 x 109/L

          -  serum creatinine &gt; 1.25 x N*

          -  total bilirubin &gt; 2.0 x N*

          -  ASAT and/or ALAT &gt; 2.5 x N* (in case of liver metastases &gt; 5 x N*)

          -  alkaline phosphatase &gt; 2.5 x N* (in case of liver metastases &gt; 5 x N*, in case of bone
             metastases &gt; 10 x N*) *N = upper limit of standard range

          -  Severe renal impairment [creatinine clearance &lt; 30 mL/min (calculated according to
             cockcroft and Gault)]
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduard Vrdoljak, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Split, Center of oncology, Croatia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduard Vrdoljak, PhD MD</last_name>
    <phone>00385-21-556-129</phone>
    <email>eduard.vrdoljak@st.htnet.hr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center of oncology</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard Vrdoljak, MD PhD</last_name>
      <phone>00385-21-556-129</phone>
      <email>eduard.vrdoljak@st.htnet.hr</email>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. dr. sc. Eduard Vrdoljak</name_title>
    <organization>Clinical Hospital Split, Center of oncology</organization>
  </responsible_party>
  <keyword>Metastatic breast cancer patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

